title: MRSA-pyomyositis in a patient with acute myelogenous leukemia after intensive chemotherapy.
abstract: BACKGROUND
  A case of methicillin-resistant Staphylococcus aureus (MRSA)-pyomyositis in association with acute myelogenous leukemia (AML) is reported. MRSA-sepsis developed in a 51-year-old Japanese man with AML, during the neutropenic period after high-dose 1-beta-d-arabinofuranosylcytosine (Ara-C). Although the MRSA-sepsis initially improved with arbekacin sulfate (ABK) administration, a high fever recurred with left thigh pain despite recovery of the neutrophil count after ABK was stopped. A computed tomographic (CT) scan showed a low-density area in the left quadriceps femoris muscle, which led to a diagnosis of pyomyositis. MRSA was cultured from the abscess aspirates. The fever and thigh pain disappeared after administration of ABK and minocycline hydrochloride (MINO), and the abscess completely disappeared with the oral administration of levofloxacin (LVFX) for about 3 months.
  
  
  CONCLUSIONS
  If an immunocompromised patient complains of fever and muscle pain after intensive chemotherapy, MRSA-pyomyositis should be considered.
authors: Department of Hematology and Immunology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan. tfukus@kanazawa-med.ac.jp
authors: Toshihiro
authors: T
authors: Fukushima
authors: Haruka
authors: H
authors: Iwao
authors: Akio
authors: A
authors: Nakazima
authors: Miyuki
authors: M
authors: Miki
authors: Tomoyuki
authors: T
authors: Sakai
authors: Toshioki
authors: T
authors: Sawaki
authors: Masao
authors: M
authors: Tanaka
authors: Yasufumi
authors: Y
authors: Masaki
authors: Yuko
authors: Y
authors: Hirose
authors: Hisanori
authors: H
authors: Umehara
mesh_terms: D000038:Abscess / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003982:Dibekacin / Q000031:analogs & derivatives / Q000627:therapeutic use; D005334:Fever / Q000517:prevention & control; D006801:Humans; D016867:Immunocompromised Host; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D008297:Male; D016106:Methicillin Resistance; D055624:Methicillin-Resistant Staphylococcus aureus / Q000472:pathogenicity*; D008875:Middle Aged; D052880:Pyomyositis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D012074:Remission Induction; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*
chemical_list: D000890:Anti-Infective Agents; D003982:Dibekacin; C031986:arbekacin